
### [NCIT:C48873](http://purl.obolibrary.org/obo/NCIT_C48873)
**Label:** Splenic Lymphoma

**Subclasses:** [NCIT:C7308](http://purl.obolibrary.org/obo/NCIT_C7308) (Splenic Diffuse Large B-Cell Lymphoma), [NCIT:C7307](http://purl.obolibrary.org/obo/NCIT_C7307) (Splenic Follicular Lymphoma), [NCIT:C7294](http://purl.obolibrary.org/obo/NCIT_C7294) (Splenic Non-Hodgkin Lymphoma), [NCIT:C7309](http://purl.obolibrary.org/obo/NCIT_C7309) (Splenic Burkitt Lymphoma), [NCIT:C4663](http://purl.obolibrary.org/obo/NCIT_C4663) (Splenic Marginal Zone Lymphoma), [NCIT:C8459](http://purl.obolibrary.org/obo/NCIT_C8459) (Hepatosplenic T-Cell Lymphoma), [NCIT:C80309](http://purl.obolibrary.org/obo/NCIT_C80309) (Splenic Diffuse Red Pulp Small B-Cell Lymphoma), [NCIT:C5095](http://purl.obolibrary.org/obo/NCIT_C5095) (Recurrent Splenic Marginal Zone Lymphoma), [NCIT:C7295](http://purl.obolibrary.org/obo/NCIT_C7295) (Splenic Hodgkin Lymphoma), [NCIT:C5096](http://purl.obolibrary.org/obo/NCIT_C5096) (Refractory Splenic Marginal Zone Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 52.66%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39862](http://purl.obolibrary.org/obo/NCIT_C39862) (Human Papillomavirus-Related Urethral Squamous Cell Carcinoma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39859](http://purl.obolibrary.org/obo/NCIT_C39859) (Bladder Inverted Papilloma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39856](http://purl.obolibrary.org/obo/NCIT_C39856) (Urothelial Dysplasia))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39845](http://purl.obolibrary.org/obo/NCIT_C39845) (Bladder Urachal Squamous Cell Carcinoma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39844](http://purl.obolibrary.org/obo/NCIT_C39844) (Bladder Urachal Urothelial Carcinoma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39834](http://purl.obolibrary.org/obo/NCIT_C39834) (Bladder Squamous Papilloma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39833](http://purl.obolibrary.org/obo/NCIT_C39833) (Schistosoma Hematobium-Related Bladder Verrucous Carcinoma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39829](http://purl.obolibrary.org/obo/NCIT_C39829) (Infiltrating Bladder Urothelial Carcinoma with Giant Cells))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39826](http://purl.obolibrary.org/obo/NCIT_C39826) (Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant without Heterologous Elements))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39825](http://purl.obolibrary.org/obo/NCIT_C39825) (Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant with Heterologous Elements))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39821](http://purl.obolibrary.org/obo/NCIT_C39821) (Infiltrating Bladder Lymphoepithelioma-Like Carcinoma))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39820](http://purl.obolibrary.org/obo/NCIT_C39820) (Infiltrating Bladder Urothelial Carcinoma, Microcystic Variant))) 39.90%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39819](http://purl.obolibrary.org/obo/NCIT_C39819) (Infiltrating Bladder Urothelial Carcinoma, Nested Variant))) 39.90%


